Invention Grant
- Patent Title: NOL3 is a predictor of patient outcome
- Patent Title (中): NOL3是患者预后的结果
-
Application No.: US12685411Application Date: 2010-01-11
-
Publication No.: US08841067B2Publication Date: 2014-09-23
- Inventor: Andrew Kung , David Ziegler
- Applicant: Andrew Kung , David Ziegler
- Applicant Address: US MI Ann Arbor
- Assignee: Dana-Farber Cancer Institute, Inc.
- Current Assignee: Dana-Farber Cancer Institute, Inc.
- Current Assignee Address: US MI Ann Arbor
- Agency: Brinks Gilson & Lione
- Main IPC: C12Q1/00
- IPC: C12Q1/00 ; C12Q1/68 ; G01N33/53 ; G01N33/574 ; A01N43/54 ; C07D471/12 ; A61K31/496 ; A61K45/06
Abstract:
The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.
Public/Granted literature
- US20100179163A1 NOL3 IS A PREDICTOR OF PATIENT OUTCOME Public/Granted day:2010-07-15
Information query
